Press coverage about Crispr Therapeutics (NASDAQ:CRSP) has trended somewhat positive recently, Accern Sentiment reports. The research firm rates the sentiment of news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Crispr Therapeutics earned a news impact score of 0.09 on Accern’s scale. Accern also assigned news articles about the company an impact score of 46.7721044802528 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
A number of equities analysts have recently commented on the company. Zacks Investment Research downgraded Crispr Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, January 25th. BidaskClub raised Crispr Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, January 25th. SunTrust Banks raised Crispr Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday, January 23rd. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $22.75 price target (down from $39.00) on shares of Crispr Therapeutics in a report on Wednesday, January 10th. Finally, Oppenheimer assumed coverage on Crispr Therapeutics in a report on Thursday, December 7th. They issued a “hold” rating for the company. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $22.81.
Shares of Crispr Therapeutics (CRSP) traded down $0.61 on Friday, reaching $40.01. The company had a trading volume of 612,595 shares, compared to its average volume of 1,070,000. The firm has a market capitalization of $1,810.00 and a P/E ratio of -125.03. Crispr Therapeutics has a 52-week low of $13.50 and a 52-week high of $45.00.
In other Crispr Therapeutics news, major shareholder Corp /De/ Celgene sold 158,718 shares of the business’s stock in a transaction that occurred on Monday, November 20th. The stock was sold at an average price of $19.02, for a total value of $3,018,816.36. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Tyler Dylan-Hyde sold 66,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $28.03, for a total value of $1,849,980.00. Following the completion of the sale, the insider now owns 25,204 shares of the company’s stock, valued at approximately $706,468.12. The disclosure for this sale can be found here. Insiders sold 1,974,168 shares of company stock valued at $39,611,064 over the last ninety days. 39.98% of the stock is currently owned by corporate insiders.
TRADEMARK VIOLATION NOTICE: This article was originally published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this article on another domain, it was copied illegally and republished in violation of international trademark & copyright legislation. The original version of this article can be accessed at https://ledgergazette.com/2018/02/17/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-crispr-therapeutics-crsp-stock-price.html.
Crispr Therapeutics Company Profile
Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.